Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines (Q38184579)

30 August 2017

title

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines (English)

1 reference

30 August 2017

Tomáš Hanke

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

3 February 2014

1 reference

Expert Opinion on Biological Therapy

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

601-616

1 reference

Vaccines: correlates of vaccine-induced immunity

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Vaccines: the Fourth Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Accelerating next-generation vaccine development for global disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Viral vectors as vaccine platforms: deployment in sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

CD8+ T cell efficacy in vaccination and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

21 January 2018

RTS,S/AS02A for malaria

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Reverse vaccinology in the 21st century: improvements over the original design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A protein particle vaccine containing multiple malaria epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Design and pre-clinical evaluation of a universal HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

HIV-1 group M conserved elements vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Hitting HIV where it hurts: an alternative approach to HIV vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

The challenge of developing universal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Targeting early infection to prevent HIV-1 mucosal transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Immune clearance of highly pathogenic SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Combined approaches for HIV cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Definition of the viral targets of protective HIV-1-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Cell-mediated Immunity to Respiratory Syncytial Virus Induced by Inactivated Vaccine or by Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Diversity considerations in HIV-1 vaccine selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

T cell cross-reactivity and conformational changes during TCR engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

HIV evolution: CTL escape mutation and reversion after transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

The design and evaluation of HIV-1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Elicitation of structure-specific antibodies by epitope scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Rational Engineering of Recombinant Picornavirus Capsids to Produce Safe, Protective Vaccine Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Programming dendritic cells to induce T(H)2 and tolerogenic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

DNA vaccines against human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Development of replication-competent viral vectors for HIV vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

New insights on adenovirus as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

MVA as a vector for vaccines against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Replicating and non-replicating viral vectors for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

T-cell quality in memory and protection: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Recombinant Mycobacterium bovis BCG as an HIV vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Antibody gene transfer for HIV immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

New adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Lessons learned from HIV-1 vaccine trials: new priorities and directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

HIV-1 vaccines and adaptive trial designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Another HIV vaccine failure: where to next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Global Eradication of Smallpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Targeting of a CD8 T Cell Env Epitope Presented by HLA-B*5802 Is Associated with Markers of HIV Disease Progression and Lack of Selection Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

T Cell Receptor Recognition Motifs Govern Immune Escape Patterns in Acute SIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Human microbial challenge: the ultimate animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.885946

10.1517/14712598.2014.885946

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference